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Patients are isolated in the hospital during the neutropenic phase after allogeneic hematopoietic stem cell
transplantation. We challenged this by allowing patients to be treated at home. A nurse from the unit visited
and checked the patient. One hundred forty-six patients treated at home were compared with matched
hospital control subjects. Oral intake was intensiﬁed from September 2006 and improved (P ¼ .002). We
compared 4 groups: home care and control subjects before and after September 2006. The cumulative inci-
dence of acute graft-versus-host disease (GVHD) of grades II to IV was 15% in the "old" home care group, which
was signiﬁcantly lower than that of 32% to 44% in the other groups (P< .03). Transplantation-relatedmortality,
chronic GVHD, and relapse were similar in the groups. The "new" home care patients spent fewer days at home
(P ¼ .002). In multivariate analysis, GVHD of grades 0 to I was associated with home care (hazard ratio [HR],
2.46; P¼ .02) and with days spent at home (HR, .92; P¼ .005) but not with oral nutrition (HR, .98; P¼ .13). Five-
year survival was 61% in the home care group as compared with 49% in the control subjects (P ¼ .07). Home
care is safe. Home care and many days spent at home were correlated with a low risk of acute GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION prompted us to improve oral nutrition in patients treated in
After chemoradiotherapy and allogeneic hematopoietic
stem cell transplantation (HSCT), patients become pan-
cytopenic. To protect them from infections, they are treated
in the hospital in laminar airﬂow rooms or reversed isolation
[1-4]. For more than a decade, we have challenged the
concept of isolation of HSCT patients in a hospital by allowing
those who live within 1 or 2 hours’ driving distance from our
unit be treated at home during the pancytopenic phase [5,6].
Russell and coworkers also allowed some of their HSCT
patients to visit home during the neutropenic phase after
transplantation [7]. Our initial idea was that patients treated
at home would have a better quality of life than if isolated in
the hospital. Compared with matched control subjects
treated in a hospital, we saw several advantages to home
care, such as earlier discharge to the outpatient clinic, fewer
days on total parenteral nutrition, and lower costs [5]. To our
surprise, patients treated at home also had less acute graft-
versus-host disease (GVHD) and lower transplantation-
related mortality (TRM). After these promising results, all
patients living within a comfortable driving distance from
the hospital were offered home care.
In amore recent comparison of home care and isolation in
the hospital, we found that acute GVHD was associated with
hospital care and poor oral nutrition [8]. This ﬁndingedgments on 319.
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home care and hospital care was to determine whether
improving oral nutrition in hospital care patients might
reduce the incidence of acute GVHD and if home environ-
ment inﬂuenced GVHD probability or not.PATIENTS AND METHODS
From March 1, 1998 until December 31, 2010, 832 patients underwent
HSCT at the Center for Allogeneic Stem Cell Transplantation. Of those, 146
patients were eligible for home care. This involved a relative or friend who
was willing to stay with the patient at home. The home was also approved
by the Department of Infectious Control and had to have a hot water
temperature of more than 50C. Potted plants and pets were removed. The
patient had to live within 1 to 2 hours’ driving distance from the hospital.
Control patients were matched with the home care patients for as many
variables as possible, including sex, age, diagnosis, stage of disease, type of
donor, stem cell source, and conditioning. The control patients were not
eligible for home care because they lived outside the Stockholm area. The
characteristics of the patients and the control subjects are given in Table 1.
Median follow-up time was 48 months in the home care group and 51
months in the control group. The study was approved by the Institutional
Review Board and the Ethics Committee of Karolinska University Hospital,
Karolinska Institutet. Informed consent was obtained.
From September 2006, oral intake was intensiﬁed in patients treated in
the hospital, using a special team of nurses who helped the patients and
encouraged them to a better oral intake. We therefore divided the material
into four groups: “old” home care (HC) before September 2006 (n ¼ 76),
“old” control subjects (C) treated in the hospital before September 2006,
“new” HC (from September 2006, n ¼ 70), and “new” C (n ¼ 70) treated in
the hospital and who received intensiﬁed nutrition.Conditioning and Information
In patients with acute lymphoblastic leukemia, conditioning consisted
of 120 mg/kg cyclophosphamide (Cy) combined with 10 Gy of total body
irradiation or fractionated irradiation: 3 Gy daily for 4 days [9]. In patientsTransplantation.
Table 1
Characteristics of Home Care Patients and Case Control Subjects Treated in
the Hospital
Home Care
(n ¼ 146)
Control Subjects
(n ¼ 146)
Age, y 47 (4e71) 46 (3e65)
Children <18 y 9 10
Sex (M/F) 86/60 86/60
Diagnosis
AML/ALL 51/16 51/17
CML/CLL 11/13 12/11
MDS/MPS 23 24
Lymphoma 14 14
Other malignancy 12 11
Nonmalignant disorder 6 6
Disease stage (E/L) 71/75 69/77
Donor age, y 37 (0e72) 36 (0e67)
Donor sex (M/F) 93/52 90/56
Donor
HLA-identical sibling 48 48
MUD 88 91
Allele MM URD 6 3
Ag MM URD 4 4
Conditioning
MAC/RIC 70/76 71/75
TBI þ Cy 33 36
Bu þ Cy 35 33
Cy þ TLI 2 2
Fludarabine þ Bu 47 45
Fludarabine þ Cy 15 12
Fludarabine þ TBI þ Cy 10 13
Fludarabine þ treosulfan 4 4
ATG 112 (77%) 110 (75%)
Female to male 18 (12%) 22 (15%)
Stem cell source
BM/PBSCs/CB 28/114/4 29/113/4
NC dose ( 108/kg) 10.5 (.2e32.7) 9.6 (.1e61.2)
CD34 cell dose ( 106/kg) 7.5 (.1e27.0) 7.4 (.1e56.4)
GVHD prophylaxis
CsA þ MTX 125 127
Prograf þ sirolimus 12 12
Other 9 7
CMV e/e 20 14
Follow-up, mo 48 (1e155) 51 (2e181)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS,
myelodysplastic syndrome; MPS, myeloproliferative syndrome; disease
stage E, early, nonmalignant, ﬁrst remission or ﬁrst chronic phase; L, late,
more advanced stages; MUD, matched unrelated donor; MM, mismatch; Ag,
antigen; URD, unrelated donor; MAC, myeloablative conditioning; RIC,
reduced-intensity conditioning; TBI, total body irradiation; Cy, cyclophos-
phamide; Bu, busulfan; TLI, total lymphoid irradiation; ATG, antithymocyte
globulin; BM, bone marrow; PBSCs, peripheral blood stem cells; CB, cord
blood; NC, nucleated cell; CsA, cyclosporine; MTX, methotrexate; CMV e/e,
cytomegalovirus seronegativity in recipient and donor.
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divided into 2 or 4 doses given for 4 days. In some patients, busulfan was
replaced with treosulfan at 12 g/m2/day for 3 days. Reduced-intensity
conditioning included ﬂudarabine at 30 mg/m2/day for 6 days combined
with busulfan at 4 mg/kg/day for 2 days or combined with Cy at 60 mg/kg
[10]. Patients with lymphomas were treated with ﬂudarabine, fractionated
total body irradiation (3 Gy/day for 2 days), and Cy 120 mg/kg.
Conditioning was given in the hospital, at which time the patients and
caregivers were given information regarding the procedure. Information
was given by nurses, doctors, a nutritionist, a physiotherapist, and a social
worker. It was important for patients and caregivers to know the staff in the
event they had questions regarding the procedure when they were at home.
Home Care
After infusion of the graft, the patient could go home. An experienced
nurse from the ward visited the patient every morning to check vital signs,
temperature, and blood pressure and to examine the patient for GVHD or
other lesions. The nurse took blood samples and gave intravenous medica-
tions, if needed. Erythrocyte transfusions were given by the nurse at home if
the patient had a hemoglobin level of less than 80 g/L, and platelet infusionswere given when the platelet count fell below 10 or 30  109/L or if there
were signs of hemorrhage [11]. Total parenteral nutritionwas given at home
when the caloric intake was below 70% of the total need. At the hospital, the
nurse and the physician went through the clinical and laboratory data. The
physician called the patient in the afternoon to tell her or him about
the laboratory tests, to check on the patient’s well-being, and to make
appropriate modiﬁcations to the medication. If needed, and if a home care
nurse was available, the nurse could visit the patient a second time. If the
patient’s temperature rose above 38.5C, the patient was readmitted to
hospital for blood cultures and intravenous antibiotics with ceftriaxone once
daily. The patient called to be readmitted to hospital if there was deteriora-
tion of his or her condition, any need of intravenous injections more than
twice daily, or if the caregiver was unable to support the patient. If stable, the
patient was allowed to go home evenwith a fever and a need for intravenous
antibiotics or parenteral nutrition. This was then continued at home.
Hospital Care
At the hospital, patients were treated in conventional single rooms with
reversed isolation and air ﬁltration. A relative or friend could stay with them
[12]. Gut decontamination consisted of 500mg oral ciproﬂoxacin twice daily
and 100 mg ketoconazole once a day until absolute neutrophil count was
above .5  109/L [13]. Treatment was the same for hospital care patients and
those treated at home. Number of days with ciproﬂoxacin was the same in
the 4 study groups. The patients could take a walk outside the hospital after
6:00 PM onweekdays and at any time duringweekends. After “ofﬁce hours,”
there are less people moving around in the corridors of the hospital who can
infect the patient. Patients with a herpes simplex virus IgG titer of more than
10,000, as determined by enzyme-linked immunosorbent assay, received
oral or intravenous acyclovir prophylaxis until the absolute neutrophil count
was more than .5  109/L. When the absolute neutrophil count was more
than .2  109/L for 2 consecutive days, the isolation was broken. Details of
supportive care are reported in detail elsewhere [5,12].
Immunosuppression and Donors
Cyclosporine was combined with 4 doses of methotrexate and given to
most patients as prophylaxis against GVHD [14]. Approximately one-third of
the patients were given grafts from human leukocyte antigen (HLA)-iden-
tical siblings, and the remaining patients received grafts fromHLA-A, -B, and
-DRb1 identical unrelated donors, typed using polymerase chain reaction-
SSP (single speciﬁc primer) high-resolution typing at the four-digit level
[15]. Granulocyte colony-stimulating factoremobilized peripheral blood
stem cells from related or unrelated donors were given tomost patients [16].
A smaller proportion of patients were given bone marrow grafts, and 4
patients in each group underwent cord blood transplantations (Table 1).
Acute GVHD of grade I was treated with prednisolone 1 to 2 mg/kg/day
divided into 2 doses.
Caloric Intake
Oral and intravenous intake was calculated as kcal/kg/day for each
patient during the ﬁrst 21 days after HSCT. The patients alone or together
with their relatives made a list of all oral intakes every day. The nurses
calculated kilocalories every day, which was noted in the charts. The
procedure was the same for patients treated at home and in the hospital.
A previous study showed a correlation between poor oral intake and
increasing grade of acute GVHD [8]. Patients treated in the hospital received
more total parenteral nutrition than those treated at home [6]. Thus, we
started a nutritional team of nurses who encouraged the hospital patients
and helped them to improve their oral intake.
Statistics
Overall survival was calculated using the Kaplan-Meier method and
compared with the log-rank test [17]. TRM, GVHD, and relapse were esti-
mated using an estimator of cumulative incidence curves taking competing
events into consideration. Univariate and multivariate risk factor analyses
for GVHD were performed using the proportional subdistribution hazard
regression model developed by Fine and Gray [18]. All P values were
2-tailed. Categorical parameters were compared using the chi-square test,
and continuous variables were compared using the Mann-Whitney test.
Analysis was performed using the cmprsk software package (developed by
Gray, June 2001 [www.statsoft.com]), Splus 6.2 software (Insightful, Seattle,
WA), and Statistica software (StatSoft, Tulsa, OK).
RESULTS
Days at Home
Patients went home on median day 1 (range, 0-8) after
HSCT. Ninety-two of 146 patients treated at home (63%) were
readmitted to the hospital. Sixty-eight of those (74%) went
Table 2
Rejection and Infections in the 4 Study Groups
Old C Old HC New C New HC P Value
n 76 76 70 70
Rejection 3 4 4 2 .83
CMV infection 43 46 38 28 .08
CMV disease 7 4 3 0 .08
HSV 12 13 4 11 .17
VZV 10 13 8 11 .77
PTLD 1 2 1 5 .15
Hem. cystitis 8 9 4 4 .56
CMV infection indicates cytomegaloviruspolymerase chain reactionpositivity;
CMVdisease, symptomaticCMV infection;HSV,herpessimplexvirus infection;
VZV, varicella-zoster virus infection; PTLD, posttransplantation lymphoproli-
ferative disorder; Hem. cystitis, hemorrhagic cystitis.
Figure 1. (A) Oral nutrition, median kcal/kg/d, in patients treated at home
(HC) and in hospital (C) before September 2006 (Old) and after this date
(New). (B) Oral nutrition, median kcal/kg/d, and grade of acute GVHD in all
patients treated at home and in hospital (n ¼ 292; P ¼ .02).
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hospital a second time. The most common reason for read-
mission was fever. However, 3 patients were readmitted
because their caregivers could not stay with them, due to
other obligations. In the "old" HC group, patients were
treated for a median of 15 days at home (range, 0-26) during
the ﬁrst month. This was statistically signiﬁcantly longer
than the median time of 12 days (range, 0-27) for the "new"
HC group (P ¼ .002).
Rejection and Infections
The incidence of rejection was similar in the 4 groups of
patients (Table 2). There was a trend of a reduced probability
of cytomegalovirus (CMV) infection (polymerase chain
reaction positivity) in the new HC group. There were no
patients with CMV disease (symptomatic CMV) in the new
HC group, in contrast to 3 to 7 cases in the other groups
(Table 2). There were no signiﬁcant differences regarding
herpes simplex virus and varicella-zoster virus infections,
Epstein-Barr virus posttransplantation proliferative disorder,
or hemorrhagic cystitis between the 4 groups.
Oral Nutrition
Oral nutrition, in kcal/kg/day, during the ﬁrst 21 days after
HSCT was signiﬁcantly better in the old HC group than in the
old C group (P ¼ .04) (Figure 1A). This was before GVHD had
any inﬂuence on oral intake. Oral nutrition was signiﬁcantly
improved in the new C group than in the old C group
(Figure 1A, P ¼ .002). The new C group with a median intake
of 26.8 kcal/kg/day was not signiﬁcantly different from the
new HC group, at 23.6 kcal/kg/day.
Graft-versus-Host Disease
The cumulative incidence of acute GVHD of grades II to IV
was 15% in the old HC group, which was signiﬁcantly lower
than the 32% and 37% in the control subjects (P < .03) and
44% in the new HC group (Figure 2A; P< .001). GVHD did not
appear during pancytopenia in these patients. Eleven HC
patients developed grades II to III acute GVHD before
discharge and spent a median 9 days (range, 0-27) at home.
The cumulative incidence of chronic GVHDwas similar in the
4 groups and ranged between 35% and 41% (Figure 2B). In the
home care patients, there was a negative correlation
between the number of days at home and the severity of
acute GVHD (Figure 2C; P ¼ .005). There was a correlation
between low oral nutrition and severity of acute GVHD (P ¼
.02) (Figure 1B). In multivariate analysis, home care (P ¼ .02)
and the number of days at home (P< .004) were correlated to
a decreased incidence of acute GVHD (Table 3). Inmultivariate analysis, good oral nutrition was not associated
with a low risk of acute GVHD (P ¼ .92; Table 3).
TRM and Relapse
At 1 year, TRMwas 12% in the old HC group and 24% in the
old C group (P ¼ .07) (Figure 3A). In the new HC group and
the new C group, the respective ﬁgures were 17% and 10%.
The probability of relapse in patients with malignancies was
not signiﬁcantly different in patients treated at home and in
control subjects (Figure 3B).
Survival and Relapse-Free Survival
Overall, there was a trend of better survival in the home
care patients; it was 61% at 6 years as opposed to 49% in the
patients treated in the hospital (P ¼ .07) (Figure 3C). Three-
year survival was 59% in the new HC group and 66% in the
old HC group. The corresponding ﬁgures were 55% and 50%
for the new and old C groups, respectively. Relapse-free
survival in patients with malignancies also tended to be
better for the 2 HC groups compared with the 2 control
groups (P ¼ .07) (Figure 3D).
DISCUSSION
During the last 5 years, we concentrated on improving
outcomes in patients treated in the hospital by mimicking
the positive effect seen with home care. Based on our expe-
riences from the home care project, we also allowed patients
treated in the hospital to go out and take a walk. This was
Figure 2. (A) Time to and cumulative incidence of acute GVHD of grades II to
IV in home care patients (HC) and control subjects (C) treated in the hospital
before September 2006 (Old) and after this date (New). (B) Time to and
cumulative incidence of chronic GVHD in home care patients (HC) and control
subjects (C) treated in the hospital before September 2006 (Old) and after this
date (New). (C) Grade of acute GVHD and days spent at home in all patients
treated at home.
Table 3
Multivariate Analysis of Factors Inﬂuencing Probability of Acute GVHD
Grades II to IV and Not Matched for in the Comparison between Home Care
and Control Patients
Factor Hazard
Ratio
95% Conﬁdence
Interval
P Value
Home care vs hospital care .41 .19e.86 .02
Oral nutrition* .98 .94e1.01 .13
Number of days at home .92 .88e.98 .004
* Median kcal/day per os during the ﬁrst 21 days after transplantation.
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used a special nutrition team of nurses to encourage patients
in the hospital to eat more, even if they had mucositis and
felt nauseated. Oral nutrition in the new C group treated in
the hospital had the best oral caloric intake, even though it
was not signiﬁcantly different from that of the home care
patients (Figure 1A). There was also a correlation between
poor oral caloric intake and severity of acute GVHD
(Figure 1B). Despite this, the incidence of acute GVHD grades
II to IV was the same in the old and new C groups and also in
the new HC group. In these 3 groups, the incidence of GVHD
was signiﬁcantly higher than in the old HC group, where theprobability of acute GVHD grades II to IV was only 15%
(Figure 2A). Improved oral caloric intake in the new control
group did not reduce the risk of acute GVHD. A previous
study from our unit showed a signiﬁcant correlation
between poor oral nutrition and severe acute GVHD [19]. It is
possible that poor oral intake due to gastroenteritis after
transplantation is a marker of acute GVHD, not the reason for
it. Damage to the gastrointestinal tract and release of lipo-
polysaccharides from Escherichia coli play a major role in the
development of gastrointestinal acute GVHD [20]. Thus, it
appears that damage to the gut rather than poor oral intake is
the reason for increased acute GVHD in our patients. It has
also been shown by colleagues at Johns Hopkins that
gastrointestinal damage is associated with acute GVHD [21].
Because the ﬁrst series of home care patients had a lower
probability of developing acute GVHD than the most recent
home care patients, we sought the reason for this discrep-
ancy. Both groups had similar caloric oral intake; therefore,
this cannot be the reason for the altered frequency of acute
GVHD. A low incidence of acute GVHD was also found to be
correlatedwith number of days at home (Figure 2C). The new
HC patients spent signiﬁcantly fewer days at home than the
old HC group (P ¼ .002). This may be the reason for the
discrepancy in probability of acute GVHD between these 2
groups. The multivariate analysis also showed that the
number of days at home was correlated with a low risk of
acute GVHD, whereas oral caloric intake was not (Table 3).
The reason patients stay at home for a shorter time is that
new physicians feel insecure and therefore want to keep
patients in the hospital after readmission, for example,
because of fever, instead of sending them home. Infectious
diseases consultants also recommend intravenous antibiotics
4 times a day with imipenem for fever of unknown origin, to
have coverage for Pseudomonas aeruginosa, although this is
a rare cause of septicemia in our patients [22]. Patients with
positive blood culture for Pseudomonas could be kept in the
hospital for appropriate treatment with antibiotics. If they do
not have septicemia requiring antibiotics several times a day,
patients are better off at home.
We speculate that the microenvironment in the hospital
may be more likely to trigger GVHD than that at home. One
possible reason might be that patients are more adapted to
the bacterial ﬂora at home. The hospital ﬂora with other
bacteria and fungi, together with viruses, may trigger GVHD.
In linewith this, studies in experimental animals have shown
that gnotobiotic mice develop less severe acute GVHD
[23,24]. A clinical study in patients with severe aplastic
anemia found that those treated in laminar airﬂow rooms
had a reduced risk of developing acute GVHD, compared
with similar patients treated in reversed isolation [25]. We
also reported a correlation between herpes virus serology in
recipients and donors and GVHD [26]. These studies and the
low incidence of acute GVHD in patients treated for many
days at home support a role of the microenvironment and
Figure 3. (A) Time to and cumulative incidence of TRM in home care patients (HC) and control subjects (C) before September 2006 (Old) and after this date (New). (B)
Time to and cumulative incidence of relapse in home care patients (HC) and control subjects (C) with hematological malignancies. Patients with nonmalignant
disorders (n ¼ 12) or solid tumor (n ¼ 10) were excluded. (C) Cumulative proportion of surviving patients in the home care group and in the control group (P ¼ .07).
(D) Cumulative proportion of relapse-free survival in the home care group (HC) and in the control group (C). Patients with nonmalignant disorders (n ¼ 12) or solid
tumor (n ¼ 10) were excluded.
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GVHD. To prove that home care and the home environment
can reduce the risk of acute GVHD, a prospective randomized
study is required. Another possibility is that patients treated
in the hospital experience more stress than those treated at
home, with an increased release of inﬂammatory cytokines
such as interferon-g, tumor necrosis factor-a, interleukin-2,
interleukin-12, and interleukin-18, which may trigger acute
GVHD [27]. Even if the home care patients were matched
with the control subjects for several risk factors as stated
previously, selection bias cannot be excluded and that
patients who were frightened or in poor condition may have
declined home care. However, no data support that anxiety
or a poor performance would favor acute GVHD. As a matter
of fact, it is very difﬁcult to predict GVHD apart from age, HLA
matching, immunosuppression, and so on, for which these
patients were matched.
Another factor that inﬂuenced the probability of acute
GVHD was whether or not there was prolonged prophylaxis
with ciproﬂoxacin (P < .01). Beelen and coworkers showed
that suppression of intestinal anaerobic bacteria reduced the
risk of acute GVHD after HSCT [13]. Reduced use of cipro-
ﬂoxacin cannot explain the discrepancies in acute GVHD
between the old and the newHC groups in the present study,
because the number of days of ciproﬂoxacin treatment was
the same in the 4 groups.In accordance with our previous studies, home care did
not affect the probability of chronic GVHD or relapse. Several
studies have shown a correlation between acute and chronic
GVHD [28,29]. Despite this, there was no correlation
between acute and chronic GVHD in patients treated at home
or in the hospital, which is in accordance with our previous
ﬁndings [30]. Chronic GVHD has a profound antileukemic
effect [31-33]. In our analysis, there was no difference in
chronic GVHD or relapse between the control subjects and
the home care patients (Figure 2A, B). In patients with
leukemias and other hematological malignancies, most
measures to decrease the incidence of GVHD, such as T cell
depletion and more efﬁcient immunosuppression, albeit
decreasing TRM, increase the probability of relapse with
similar survival or leukemia-free survival long term [34-36].
With home care, acute GVHD and TRM decreased. However,
the probability of chronic GVHD and relapse was the same as
in patients treated in the hospital; subsequently, long-term
survival was improved [30]. Thus, home caredwhile
decreasing GVHD-related deathdmaintained the graft-
versus-leukemia effect [37].
Survival and progression-free survival tended to be better
in the home care patients than in the control subjects
(P ¼ .07) (Figure 3C, D). However, statistical signiﬁcance was
not reached. Despite an increased risk of acute GVHD in the
new HC group, survival and progression-free survival were
O. Ringdén et al. / Biol Blood Marrow Transplant 19 (2013) 314e320 319similar to those in the old HC group where the patients had
a lower risk of developing acute GVHD. This is probably due
to the improved outcome we have seen in our patients in
more recent years, perhaps because of several improvements
and developments in the last few years at our unit [38]. Apart
from a low risk of acute GVHD, there are several other
advantages of home care, such as lower costs, better use of
hospital beds, and better well-being for the patients and
their relatives [6,8,16,39]. Most importantly, patients treated
at home havemore control of their own situation, whichmay
affect compliance and activities and may improve the overall
quality of life of the patient. In the hospital, the staff hasmore
control, and this may pacify the patient. Quality of life of the
patient was analyzed and will be published as a separate
study. The caregivers also ﬁlled out a questionnaire, which
will be analyzed separately. Most caregivers were enthusi-
astic about home care. A handful of the caregivers were
a little anxious, but this could be handled by help of the
nurses and frequent telephone calls from the physicians.
None of the caregivers experienced burnout.
In conclusion, despite the improved oral intake in patients
treated in the hospital in recent years, the incidence of acute
GVHD has not decreased. We found a correlation between
low incidence of acute GVHD and the number of days spent
at home with home care.ACKNOWLEDGMENTS
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